Safety and efficacy of interleukin-6-receptor inhibitors in the treatment of neuromyelitis optica spectrum disorders: a meta-analysis
Abstract Background Interleukin-6-receptor inhibitors like Tocilizumab and Satralizumab are showing promising results in the treatment of Neuromyelitis Optica spectrum disorder (NMOSD). We aimed to investigate the efficacy and safety of various Interleukin-6-receptor inhibitors in the management of...
Guardado en:
Autores principales: | Sanjeev Kharel, Suraj Shrestha, Rajeev Ojha, Neha Guragain, Rakesh Ghimire |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f636e8b70e004c17b9339b5d2b02f9fa |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Area postrema syndrome in neuromyelitis optica spectrum disorder: diagnostic challenges and descriptive patterns
por: Eman M. Khedr, et al.
Publicado: (2021) -
Cytokines and chemokines expression in serum of patients with neuromyelitis optica
por: Ai NP, et al.
Publicado: (2019) -
Complexity and wide range of neuromyelitis optica spectrum disorders: more than typical manifestations
por: Han J, et al.
Publicado: (2017) -
Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder
por: Bo Chen, et al.
Publicado: (2017) -
The role of interleukin-24 in atopic dermatitis
por: Yen Hai Vu, et al.
Publicado: (2021)